Stock Detail
GTX INC
Biotechnology
GTXI @ Yahoo Finance | GTXI Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $3.16 | $3.40 | $-0.20 | -5.95% | 0.00 | $3.36 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $3.33 | $3.07 | 298,780 | 198.42M | 192,787 | -4.86 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 3.54 | 3.35 | 3.21 | 3.02 | 2.88 |
Stock Profile
GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics primarily related to the treatment of serious men's health conditions and oncology. The company's drug discovery and development programs focus on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. It markets FARESTON, a toremifene citrate tablets, for the treatment of metastatic breast cancer. GTx develops ACAPODENE for two separate indications in men, a Phase III clinical trial product, for the prevention of prostate cancer in high risk men, and a Phase III clinical trial product for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer. The company also develops andarine, a selective androgen receptor modulator (SARM); as well as a second SARM, ostarine, for andropause and other chronic conditions related to aging, including sarcopenia. Further, its preclinical pipeline includes the specific product candidates prostarine, a SARM for benign prostatic hyperplasia, and andromustine, an anticancer drug, for hormone refractory prostate cancer. Additionally, it develops andarine for the treatment of cachexia from various types of cancer. The company has joint collaboration and license agreement with Ortho Biotech Products L.P. for the clinical development of andarine and specified backup SARM compounds. It also has collaboration agreements with Hybritech, Inc., diaDexus, Inc., and Tessera, Inc. GTx was co-founded by Mitchell S. Steiner and Marc S. Hanover in 1997. The company is based in Memphis, Tennessee.